Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 NEW YORK, March 28, 2024 BUSINESS WIRE )--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are thrilled to welcome Colleen as Nuvation Bio's first Chief Commercial Officer. She is an accomplished leader who has developed innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines. Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI®," said David Hung, M.D., Founder, President, and Chief
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Completes Acquisition of AnHeart TherapeuticsBusiness Wire
- Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]Seeking Alpha
NUVB
Earnings
- 11/2/23 - Beat
NUVB
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/18/24 - Form S-8
- 4/11/24 - Form 4
- NUVB's page on the SEC website